RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC33H42F3N9O2S2

InChIKeyBGGALFIXXQOTPY-NRFANRHFSA-N

CAS Registry2134675-36-6

Clinical Trials associated with Ziftomenib

NCT06930352

/ Not yet recruitingPhase 2IIT

Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction or Other Therapy

This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangements involving the KMT2A gene. These mutations result in activation of the menin pathway. Menin is a type of protein in the body that helps to regulate some of the naturally occurring processes in the body, but can also be involved in some types of cancers. Ziftomenib blocks this menin pathway and may prevent the cancer cells from continuing to grow. Giving ziftomenib may kill more cancer cells in patients with NPM1 mutated or KMT2A rearranged AML that are not eligible to receive standard therapy.

Start Date10 Jan 2026

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+1]

NCT07007312

/ RecruitingPhase 3

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells.
This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fit patients will receive (a) the SOC therapies cytarabine and daunorubicin, plus either ziftomenib or a placebo during a first treatment phase called induction, (b) cytarabine plus either ziftomenib or a placebo during a second treatment phase called consolidation, and (c) ziftomenib or a placebo during a third treatment phase called maintenance.
The physician will determine which study is the appropriate treatment for the patient, but neither the patient nor their physician will know whether the patient has been assigned to receive ziftomenib or a placebo. This design is called "double-blinded".

Start Date26 Sep 2025

Sponsor / Collaborator

Kura Oncology, Inc.

NCT06769490

/ RecruitingPhase 1

Phase 1 Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

The goal of this all-oral combination is to deliver safe and effective therapy for the largest portion of AML subtypes (NPM1mt, KMT2Ar, NUP98r
40-45%).

Start Date10 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Ziftomenib

100 Translational Medicine associated with Ziftomenib

100 Patents (Medical) associated with Ziftomenib

Literatures (Medical) associated with Ziftomenib

01 Nov 2025·CURRENT OPINION IN ONCOLOGY

The role of menin inhibitors in acute myeloid leukemia

Review

Author: Marconi, Giovanni ; Isidori, Alessandro

Purpose of review:

Acute myeloid leukemia (AML) characterized by NPM1 mutations or KMT2A rearrangements depends on abnormal epigenetic programs mediated by menin, a critical scaffold protein for sustaining the expression of oncogenic HOX/MEIS1 genes. Therefore, menin inhibitors have become a promising class of AML treatments.

Recent findings:

Early-phase trials have shown that agents such as revumenib, ziftomenib, bleximenib, and enzomenib are active, particularly in relapsed/refractory disease, with 23–48% of patients achieving composite complete remission. However, the durability of single-agent treatment remains limited, and resistance mechanisms, such as MEN1 mutations or transcriptional reprogramming, have been identified. Consequently, combination approaches involving venetoclax, hypomethylating agents, or chemotherapy are being investigated to improve response depth and duration. Recent SAVE, KOMET-007, and cAMeLot-2 trials have demonstrated high overall response rates (68%-100%) and encouraging MRD-negative complete remissions when combining menin inhibitors with venetoclax-based regimens. This has been observed even in patients who have previously received venetoclax. Combinations with intensive chemotherapy (e.g., 7 + 3) in the frontline setting have also yielded high CRc rates (up to 94% in NPM1-mutated AML) without exacerbating toxicity.

Summary:

These findings justify the integration of menin inhibitors into the AML therapeutic landscape, and support ongoing randomized trials to confirm their benefit in both frontline and relapse or refractory settings.

01 Nov 2025·JOURNAL OF CLINICAL ONCOLOGY

Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML

Article

Author: Balasubramanian, Suresh ; Schwarzer, Adrian ; Altman, Jessica K. ; Garcia, Olga Salamero ; Papayannidis, Cristina ; Redner, Robert L. ; Foran, James ; Fathi, Amir T. ; Heidel, Florian ; Madanat, Yazan F. ; Riches, Marcie ; Heidel, Florian H. ; Bergeron, Julie ; Pettit, Kristen ; de la Fuente Burguera, Adolfo ; Issa, Ghayas C. ; Corum, Daniel ; Rodríguez-Arbolí, Eduardo ; Deeren, Dries ; Zhang, Zijing ; del Castillo, Teresa Bernal ; Salamero Garcia, Olga ; Heiblig, Maël ; Ades, Lionel ; Venditti, Adriano ; Esteve Reyner, Jordi ; Soifer, Harris S. ; Walter, Roland B. ; Peterlin, Pierre ; Lanza, Francesco ; Ulrickson, Matthew ; Wang, Eunice S. ; Penedo, Agustín ; Giannini, Caterina ; Berthon, Céline ; Khawandanah, Mohamad ; Baer, Maria R. ; Elsawy, Mahmoud ; Erba, Harry ; Tabachri, Marilyn ; Roboz, Gail J. ; Pigneux, Arnaud ; Leoni, Mollie ; Shah, Mithun ; McCloskey, James ; Redner, Robert ; Shah, Mithun V. ; Mitra, Amitava ; Fedorov, Kateryna ; Montesinos, Pau ; Barabé, Frederic

PURPOSE:

Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1 -mutated ( NPM1 -m) and KMT2A -rearranged AML in the KOMET-001 phase I trial.

METHODS:

In the registration-enabling phase II part of KOMET-001, patients with relapsed/refractory NPM1 -m AML received ziftomenib 600 mg once daily. The primary end point was the rate of complete remission with full hematologic recovery (CR)/CR with partial hematologic recovery (CRh).

RESULTS:

From January 26, 2023, to May 13, 2024, 92 patients (median age, 69 years [range, 33-84]) were treated. The primary end point was met, with a CR/CRh rate of 22% (95% CI, 14 to 32; P = .0058); 61% were negative for measurable residual disease. Overall response rate was 33% (95% CI, 23 to 43), with a median duration of 4.6 months (95% CI, 2.8 to 7.4). Prespecified subgroup analyses showed comparable CR/CRh regardless of previous therapy, including venetoclax, or type of comutations. Median overall survival was 6.6 months (95% CI, 3.6 to 8.6). Common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome occurred in 25% of patients (15% grade 3; no grade 4-5) and was manageable with protocol-defined mitigation. Three patients (3%) discontinued treatment because of ziftomenib-related adverse events.

CONCLUSION:

Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory NPM1 -m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.

01 Sep 2025·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacy

Article

Author: Kalfah, Anas ; Dali, Sara Al ; Mohamed, Shehab F ; Al-Mashdali, Abdulrahman F

BACKGROUND:

Menin inhibitors represent a novel therapeutic approach targeting the Menin-KMT2A interaction in acute leukemias with KMT2A rearrangements or NPM1 mutations. This scoping review synthesizes current clinical evidence for emerging Menin inhibitors in development.

METHODS:

We systematically analyzed clinical trials, conference proceedings, and regulatory documents regarding Menin inhibitors in clinical development through December 2024. Primary outcomes included response rates, minimal residual disease (MRD) status, and safety profiles.

RESULTS:

Thirteen clinical trials investigating six Menin inhibitors (Revumenib, Ziftomenib, Bleximenib, BMF-219, DS-1594, and Enzomenib) were identified. Revumenib demonstrated consistent efficacy across five pivotal trials, achieving MRD-negative rates of 70-90 % in both KMT2A-rearranged and NPM1-mutated leukemias, leading to FDA approval in November 2024. Ziftomenib showed particular efficacy in NPM1-mutated cases but exhibited a higher incidence of differentiation syndrome (30 %) in KMT2A-rearranged patients. Bleximenib reported a 93 % overall response rate, pending MRD validation. Early resistance emergence, primarily through MEN1 mutations, was observed across trials, emerging as early as two treatment cycles.

CONCLUSIONS:

Menin inhibitors demonstrate promising clinical activity in molecularly defined leukemias, with Revumenib establishing proof-of-concept for this therapeutic approach. However, challenges remain, including resistance development, optimal timing of therapy initiation, and determination of effective combination strategies. Larger randomized trials with extended follow-up are needed to establish long-term efficacy and safety profiles. The rapid clinical development of multiple agents in this class suggests an expanding role for Menin inhibitors in leukemia treatment paradigms.

163

News (Medical) associated with Ziftomenib

14 Nov 2025

·www.biopharmadive.com

Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal

Today, a brief rundown of news from Pfizer and Alkermes, as well as updates from Kura Oncology, Gilead Sciences and Zealand Pharma that you may have missed.Pfizer said Thursday it has closed its $10 billion deal to acquire GLP-1 drug developer Metsera, less than a week after the target company agreed to the final offer made by the big pharma. The Federal Trade Commission had already signed off on the acquisition first announced Sept. 22, amid a bidding war sparked by counteroffers from Wegovy manufacturer Novo Nordisk. With the acquisition complete, Pfizer can advance our shared goal of further developing Metseras five experimental metabolic drugs for obesity, Pfizer CEO Albert Bourla said in a statement. Jonathan GardnerAs the Metsera saga winds down, another bidding war is just beginning. Weeks after Avadel Pharmaceuticals agreed to sell to fellow Dublin-based drugmaker Alkermes, it has now received an unsolicited offer from Lundbeck. The Alkermes deal could hand Avadel investors up to $20 per share, while the offer from Lundbeck goes as high as $23 per share. In a statement, Avadel said terms of the Alkermes deal allow it to still talk and negotiate with Lundbeck. But, so far, Avadels board has not determined whether this new proposal is superior, nor has it changed its recommendation in support of the Alkermes acquisition. Alkermes, meanwhile, said its own board is weighing options with the help of company advisors.Avadelsells a daytime sleepiness medicine that analysts from Jefferies expect to eventually generate north of $550 million in annual sales. Jacob BellIn other Alkermes news, the company announced on Wednesday positive results from a mid-stage clinical trial that evaluated different doses of an experimental medicine in people with Type 2 narcolepsy. The trial used two key measures: a daytime sleepiness questionnaire and a test that puts patients in a dark, quiet and calm room and tasks them with staying awake. According to Alkermes, participants taking a high dose of its medicine, alixorexton, did significantly better on both tests compared to their placebo-treated counterparts. Those on a middle dose did substantially better on only the latter measure. The companys share price dipped about 7% on the news. Paul Matteis, an analyst at the investment firm Stifel, wrote in a note to clients that the results were messier than some investors had hoped to see. Even so, Matteis and his team still see alixorexton as a viable product commercially. Jacob BellThe Food and Drug Administration on Thursday approved an oral medicine Kura Oncology and Kyowa Kirin have been developing for leukemia. Called Komzifti and previously known as ziftomenib, the drug has been cleared for people with treatment-resistant acute myeloid leukemia expressing a mutation called NPM1 and who don't have other good treatment options. The clearance makes Komzifti the second so-called menin inhibitor recently approved for these malignancies, following Syndax Pharmaceuticals' Revuforj. But Komzifti doesn't have a safety warning cautioning of the risk of an abnormal heart rhythm, a “major winning factor“ that may separate it from Syndax's drug, wrote Jefferies analyst Roger Song. Kura and Kyowa Kirin share rights to Komzifti through a 2024 deal. Ben FidlerGilead Sciences said a single-tablet combination of two of its HIV drugs succeeded in the first of two Phase 3 trials. Study recruits were taking between two and 11 pills per day at the start of the trial, Artistry-1, before they were randomized to either continue on or switch to a one-tablet form of Gileads bictegravir and lenacapavir. Gilead said Thursday that its drug proved non-inferior to the multitablet regimens in those enrollees, all of whom are adults whose HIV-1 had been suppressed to very low levels. Gilead has a second Phase 3 study underway, with results expected by the end of the year. Both trials would form the basis of a future regulatory filing. Delilah AlvaradoZealand Pharma said in an earnings report Thursday that it will stop developing an experimental weight-loss drug called dapiglutide. The company initially planned to advance the drug, which targets the gut hormones GLP-1 and GLP-2, into Phase 2b testing following positive Phase 1 results in June. But Zealand now intends to focus on programs with the greatest potential for clinical differentiation and long-term value creation, it said. Two of those prospects, petrelintide and survodutide, are either in or nearing late-stage testing. Delilah Alvarado '

Drug ApprovalAcquisitionPhase 3Phase 2Clinical Result

13 Nov 2025

·www.fiercepharma.com

Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval

While specific treatment options for the roughly one-third of AML patients with NPM1 mutations have historically been limited, Syndax Pharmaceuticals broke new ground in late October when the FDA cleared its drug Revuforj as the first menin inhibitor in the indication. Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia.On Thursday, the FDA signed off on Kura’s menin inhibitor ziftomenib as a new treatment for adults with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible nucleophosmin 1 (NPM1) mutation. To qualify for the treatment, which will be marketed under the brand name Komzifti, patients must not be a good fit for any alternative treatments, the FDA said in a Nov. 13 approval announcement.While specific treatment options for the roughly one-third of AML patients with NPM1 mutations have historically been limited, Syndax Pharmaceuticals broke new ground in late October when the FDA cleared its drug Revuforj as the first menin inhibitor in the indication. Syndax’s drug was originally approved last November to treat a genetic type of leukemia called lysine methyltransferase 2A (KMT2A).The two meds, both members of the same class, will now likely compete directly over the indication.NPM1 mutations rank among the most common founder mutations in AML, Kura and Kyowa Kirin said in a joint press release Thursday. Roughly 20% of patients with NPM1-m AML do not respond to frontline therapy, and of those who do, some 70% will relapse within three years, according to the partners. The FDA granted its green light after reviewing data from the partners’ pivotal KOMET-001 trial, in which 21.4% patients on Komzifti achieved complete remission (CR) or CR with partial hematologic recovery (CRh), Kura and Kyowa Kirin said in their release. The median duration of remission among those who achieved CR or CRh clocked in at 5 months, the partners said. Further, 88% of patients who hit either CR or CRh did so within half a year of starting treatment with Komzifti, Kura and Kyowa Kirin added.Komzifti will carry a boxed warning for differentiation syndrome—a potentially severe reaction to certain leukemia treatments—though patients and doctors applying more scrutiny to which drugs they prescribe alongside Komzifti can ease those potential risks, according to the companies’ approval announcement. The drug also bears precautions around QTc interval prolongation and embryo-fetal toxicity.Syndax’s Revuforj label bears similar warnings and precautions, with its boxed warnings discussing risks of differentiation syndrome, QTc prolongation and the fast heart rhythm condition Torsades de Pointes.The safety profile of Kura and Kyowa's drug "overall looks a bit better" than that for Revuforj, analysts at Mizuho Securities concluded, adding that a differentiation syndrome boxed warning for the menin inhibitor class comes as "[n]o real surprise." “Komzifti combines compelling efficacy, a favorable safety profile, compatibility with concomitant medications, and convenient once-daily oral administration in a population with few effective treatment options,” Troy Wilson, Ph.D., CEO of Kura, said in a statement. “These features highlight Komzifti’s potential to serve as the menin inhibitor of choice in its approved indication.”Kyowa Kirin hitched its wagon to Kura and ziftomenib just shy of a year ago, paying $330 million upfront in November 2024—and pledging up to $1.1 billion in potential milestones—to split development and commercialization on the asset.Under the deal, Kura is in charge of development, regulatory and commercial strategy for Komzifti in the U.S., as well as manufacturing, while Kyowa Kirin is holding down R&D and marketing duties outside the U.S. In their press release, the partners said that following the approval, they will now “jointly perform certain commercialization activities in accordance with a co-created U.S. territory commercialization plan.”Kura’s stock was trading up around 1% on Thursday morning. Editor's note: This story was updated to clarify information on Komzifti's label, and to include analyst commentary.

Drug ApprovalClinical ResultClinical Study

13 Nov 2025

·endpoints.news

FDA approves Kura and Kyowa Kirin's drug for form of acute myeloid leukemia

The FDA gave the go-ahead to Kura Oncology and Kyowa Kirin’s treatment for certain acute myeloid leukemia patients, just weeks after a rival drug was approved for a similar population. Thursday’s approval is the first for ziftomenib, which will be branded as Komzifti. The drug is cleared for use in adult patients with NPM1-mutated acute myeloid leukemia whose disease has returned or stopped responding to treatment and who have no good alternative options. The US list price for a one-month supply of Komzifti is $48,500, Kura told Endpoints News . Komzifti blocks a cell growth protein called menin, on which researchers believe this type of AML is dependent. There are roughly 22,000 people in the US diagnosed with AML each year, according to the American Cancer Society, and roughly a third of those cases bear NPM1 mutations. On Oct. 24, Syndax Pharmaceuticals won approval for its menin inhibitor Revuforj in AML with NPM1 mutations. However, there are some differences between the approval of Kura and Kyowa Kirin’s drug, which they are jointly commercializing in the US, and the FDA nod for Revuforj. Syndax’s drug came with a black box warning for differentiation syndrome, QTc prolongation and Torsades de Pointes. Differentiation syndrome is a known complication of leukemia treatment, while the latter two are serious heart activity abnormalities. Kura’s drug also comes with a black box warning for differentiation syndrome, but a less alarming warning on QTc prolongation. In addition, Kura’s drug was approved for adults only, while Syndax’s drug was approved for children and adults. Komzifti was approved on data from a Phase 1/2 trial called KOMET-001 that showed it led to a 21.4% complete remission rate with full or partial blood count recovery in 112 patients. The approval came more than two weeks ahead of the FDA’s deadline of Nov. 30.

Drug ApprovalAccelerated Approval

100 Deals associated with Ziftomenib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute myeloid leukemia with mutated NPM1	United States	Kura Oncology, Inc.	13 Nov 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Phase 2	United States	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Belgium	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Canada	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	France	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Germany	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Italy	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Poland	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Spain	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	United Kingdom	Kura Oncology, Inc.	12 Sep 2019
Mixed phenotype acute leukemia	Phase 2	United States	Kura Oncology, Inc.	12 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04067336 (KOMET-001, Pubmed \| J Clin Oncol)	Phase 1/2	Acute myeloid leukemia with mutated NPM1 NPM1-mutated	92	Ziftomenib 600 mg	unklleezdr(batouqzwqw) = hrqwhnjpdl fzbequwbow (nhwcssezdn, 14 - 32) View more	Positive	01 Nov 2025
NCT04067336 (KOMET-001, ASCO2025) Manual	Phase 1/2	Acute myeloid leukemia with mutated NPM1 NPM1 Mutation	112	Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 1b/2)	iyyeszahkj(gwuozuzmfc) = edyphkhoct ytrqszzoom (oapypxfnmm, 17 - 34) View more	Positive	30 May 2025
				Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 2)	iyyeszahkj(gwuozuzmfc) = xrpcbrpske ytrqszzoom (oapypxfnmm, 15 - 33)
NCT04067336 (KOMET-001, EHA2025)	Phase 1/2	Acute myeloid leukemia with mutated NPM1 NPM1-mutant	112	Ziftomenib 600 mg QD	jfnpyioukz(gxqlwjodps) = yasjyplllz aiyjrragrb (iqtafifybq, 17 - 34) View more	Positive	22 May 2025
NCT05735184 (KOMET-007, EHA2025)	Phase 1	Acute myeloid leukaemia with 11q23 abnormality \| Acute myeloid leukemia with mutated NPM1 NPM1-m \| KMT2A-r	51	Ziftomenib 600 mg QD + 7+3 induction	hqgufseorj(hqcyzjdqig) = febrile neutropenia (47%), decreased platelet count (31%), anemia (22%), decreased neutrophil count (20%), decreased white blood cell count (16%) pvuvejcxkp (xrpimrhykp ) View more	Positive	14 May 2025
NCT04067336 (KOMET-001, Company_Website) Manual	Phase 1/2	Acute Myeloid Leukemia NPM1 Mutation	-	Ziftomenib	gupkwgwyzv(uoeexvpmoj) = The KOMET-001 trial achieved its primary endpoint of CR plus CR with partial hematological recovery (CRh) and the primary endpoint was statistically significant. vdkacrkmlm (qflxvgliue ) Met View more	Positive	07 Feb 2025
KOMET-007 (GlobeNewswire) Manual	Phase 1	Acute myeloid leukemia with mutated NPM1 \| Acute Leukemia with a KMT2A Translocation First line NPM1 Mutation \| KMT2A Rearrangement	54	ziftomenib +venetoclax/azacitidine	vpnjnsuybh(vppkxdtbid) = bfteepsttx mugfijpbcs (fupewmhyjc ) View more	Positive	09 Dec 2024
				Ziftomenib+cytarabinecytarabine/daunorubicindaunorubicin	vpnjnsuybh(vppkxdtbid) = mebnjboscu mugfijpbcs (fupewmhyjc ) View more
ASH2024	Not Applicable	-	-	Ziftomenib 200 mg	lkcjvpsgwb(enuurlyqvo) = rbejvnutod afozxmxons (gcrajwwwrt ) View more	-	08 Dec 2024
				Ziftomenib 400 mg	lkcjvpsgwb(enuurlyqvo) = cxsioldhpe afozxmxons (gcrajwwwrt ) View more
ASH2024	Not Applicable	-	-	Ziftomenib 200 mg	xmbdixnikn(fvtcndjpot) = ylumztciaj bfszsqcgnr (egsqpjtbtm )	-	07 Dec 2024
				Ziftomenib 400 mg	xmbdixnikn(fvtcndjpot) = yznzfcvmwr bfszsqcgnr (egsqpjtbtm )
NCT04067336 (KOMET-001, Pubmed \| Lancet Oncol) Manual	Phase 1/2	Acute Myeloid Leukemia NPM1 Mutation \| KMT2A Rearrangement	83	Ziftomenib 50-1000 mg	zxtjmeacnc(qdsxgbcese) = the most common grade 3 or worse treatment-emergent adverse events were anaemia (20 [24%]), febrile neutropenia (18 [22%]), pneumonia (16 [19%]), differentiation syndrome (12 [15%]), thrombocytopenia (11 [13%]), and sepsis (ten [12%]). uvbvcmzgvz (lzndvjqwxo ) View more	Positive	01 Oct 2024
NCT05735184 (KOMET-007, Corporate Publications) Manual	Phase 1	Acute myeloid leukaemia with 11q23 abnormality \| Acute myeloid leukemia with mutated NPM1 First line KMT2A Rearrangement \| NPM1 Mutation	20	ziftomenib+SOC	qdkbhhpuaw(imswjvcmyw) = No differentiation syndrome events of any grade were reported, and no dose-limiting toxicities, evidence of QTc prolongation, drug-drug interactions or additive myelosuppression were observed. jzgedwsses (ijphhvxuvf )	Positive	30 Jan 2024
				ziftomenib+SOC (ziftomenib and 7+3)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ziftomenib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation